A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Virginia Tech researchers have shown that memory loss in aging may be reversible. Using CRISPR tools, they corrected molecular disruptions in the hippocampus and amygdala, restoring memory in older ...

Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

Aziz Ansari, an award-winning actor, director, writer and comedian, brings his “Hypothetical Tour” to the Gallo Center. He co ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.